菲科林-A通过抑制ILC2-驱动的2型炎症来保护过敏喘
Yu-Ke Xie1,2, Shan-Shan Xu1, Yong-Shuai Li2,3
1Hubei Province Key Laboratory of Allergy and Immunology, Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, China.
Allergy
|July 25, 2025
概括
菲科林-A (FCN-A) 缺乏通过促进2型炎症加剧过敏性喘. 补充FCN-A可以预防喘,突出其抑制肺炎的治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 过敏研究 研究过敏
背景情况:
- 2型炎症是喘病原体的核心,涉及先天性和适应性免疫力.
- 菲科林 (FCN) -2及其小鼠同类FCN-A是启动莱克补充系统并影响呼吸道免疫力的关键模式识别分子.
- 在过敏性喘中,FCN-2/A的特定作用在很大程度上仍未被探索.
研究的目的:
- 在过敏性喘的背景下调查Ficolin-A (FCN-A) 的作用.
- 为了确定FCN-A缺乏对喘发展和严重性的影响.
- 探索FCN-A作为过敏性喘治疗剂的潜力.
主要方法:
- 用ELISA测量了喘患者和健康对照者的血清Ficolin-2和IgE水平.
- 在野生型 (WT) 和FCN-A淘汰赛 (KO) 小鼠中建立了室内灰尘 (HDM) 诱导的喘模型.
- 免疫细胞群 (ILC1/2/3),转录因子表达 (GATA3,T-bet,RORγt),细胞因子水平和呼吸道炎症标志物通过流细胞计,RT-qPCR,西斑和ELISA进行了分析.
主要成果:
- 在过敏性喘患者和小鼠模型中观察到较低的血清FCN-2/FCN-A水平.
- FCN-A KO小鼠表现出恶化的喘症状,包括增加的IgE,气道过敏反应和炎症.
- 缺乏FCN-A导致ILC1数量减少,ILC2数量增加,II型细胞因子升高,GATA3表达受损.
- 外源性FCN-A的使用通过抑制ILC2s和2型炎症来改善喘症状.
结论:
- 菲科林-A (FCN-A) 在过敏性喘中起着保护作用.
- FCN-A抑制肺部ILC2驱动的2型炎症和IgE介导的适应性免疫.
- FCN-A代表了管理过敏喘的潜在治疗标.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
464
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
464
01:19Antiasthma Drugs: Leukotriene Modifiers
482
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
482
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
01:20Asthma: Pathogenesis and Management
597
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
597
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
397
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
397
01:17Drugs Used in Lower Respiratory Disorders: Overview
589
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
589